At SCCT24 in Washington, D.C., Keya Medical presented DeepVessel CT FFR technology. Keya Medical’s booth was a hub of activity, with healthcare professionals interested to learn about the advancements of DeepVessel FFR and the development of CCTA-based plaque analysis for evaluating plaque characteristics and Fat Attenuation Index (FAI). Together with DVFFR, the plaque analysis can provide a complete picture of CAD in terms of anatomy, physiology, and plaque information to help physicians confidently assess a patient’s risk for coronary artery disease and provide a personalized treatment plan.
The SCCT2024 conference in Washington, D.C. emphasized the transformative role of AI in cardiovascular CT imaging. With near-record abstract submissions, the event showcased AI-driven advancements. Key sessions included the AI/ML Workshop, which addressed clinical care gaps in coronary artery disease and valvular heart disease through AI/ML solutions. Dr. Todd C. Villines highlighted AI’s potential to revolutionize cardiovascular imaging by improving diagnostic precision and patient care. The conference underscored AI’s critical role in the future of cardiovascular CT, fostering innovation and collaboration in the field. For more details, read the full article published by Diagnostic and Interventional Cardiology (DAIC).
We want to share highlights and links to abstracts of notable research presented at SCCT24.
AI in Coronary Computed Tomography Angiography (CCTA) and the Fat Attenuation Index (FAI)
At the 2024 Society of Cardiovascular Computed Tomography (SCCT) conference, numerous workshops, presentations, and publications focused on the integration of artificial intelligence (AI) in cardiovascular imaging, specifically highlighting Coronary Computed Tomography Angiography (CCTA) and the Fat Attenuation Index (FAI). These sessions showcased the latest research and practical applications of AI in enhancing diagnostic precision and patient outcomes.
Brittany Weber, MD, PhD, from Brigham and Women’s Hospital, was honored with the 2024 Young Investigator Awards (YIA) for her groundbreaking research on the “Frequency, Prevalence, And Outcomes Of Incidentally Detected Coronary Artery Calcium Using AI Analysis Among Patients With Immune Mediated Inflammatory Diseases.” Her study underscores the critical role of AI in detecting CAC, offering better guidance for preventative therapies among IMID patients, and addressing the limitations of traditional cardiovascular risk calculators.
Workshops and Presentations:
- Prevalence and Prognostic Implications of Incidentally Detected Coronary Artery Calcium Using AI Analysis Among Individuals with Immune Mediated Inflammatory Diseases: Brittany Weber, MD, PhD presented a study that utilized AI to detect coronary artery calcium (CAC) in patients with immune-mediated inflammatory diseases (IMID), demonstrating over 50% prevalence and linking CAC with adverse cardiovascular outcomes.
- Optimizing Preventive Cardiology: Harnessing AI for Early Detection of Coronary Artery Disease: This observational study by Corewell Health implemented AI in electronic medical records (EMR) to analyze chest CT scans, identifying a significant number of new patients with medium or high CAC and improving overall patient care.
- AI Empowering Early Detection of CAD Patients for Improved Cardiac Care: Jefferson Einstein Hospital’s AI implementation to screen large populations, identify high CAC levels, and facilitate follow-up consultations and treatments.
- Artificial-Intelligence-Based Detection of Coronary Artery Calcium on Chest CT to Enhance Cardiovascular Risk Assessment: This study by Massachusetts General Hospital and Brigham & Women’s Hospital found a significant correlation between CAC levels and lipoprotein(a) (Lp(a)), suggesting AI’s potential in identifying at-risk individuals.
- Opportunistic Screening of Coronary Artery Calcification on Non-Gated Conventional CT Scans Using AI: Rabin Medical Center’s study utilized AI to analyze non-gated chest CT scans, identifying patients with severe CAC and directing them to preventive cardiology clinics.
Clinical Trials and Registries Award
Kenneth Chan, MBBS
The Society of Cardiovascular Computed Tomography (SCCT) will honor Kenneth Chan, MBBS, as the recipient of the 2024 SCCT Clinical Trials and Registries Award (CTRA). Chan conducted the winning study Socioeconomic disparities and the prognostic value of coronary inflammatory risk from routine coronary CT angiography: The Oxford Risk Factors and Non-Invasive Imaging, ORFAN study.
This research investigates the link between coronary inflammation and social deprivation, a known driver of cardiovascular disease. It evaluates the Fat Attenuation Index (FAI) Score on routine CCTA to predict cardiovascular outcomes across different socioeconomic classes, and ethnicity groups, and in the presence or absence of obstructive coronary artery disease (CAD).
Best Abstract Award
Alexander Razavi, MD MPH, PhD
Modeling Allocation Of Semaglutide According To Coronary Artery Calcium And Body Mass Index In Persons Without Clinical Atherosclerotic Cardiovascular Disease And Diabetes: The Multi-Ethnic Study Of Atherosclerosis
Mona Ahmed, MD, PhD
High-Risk Shear Stress Metrics Predict Acute Coronary Syndromes By Coronary Computed Tomography Angiography
Milan Vecsey-Nagy, MD, PhD
Ultrahigh-resolution Photon-counting Detector CT Reclassifies Nearly Half Of Patients To A Lower CAD-RADS Category: Results From A Prospective, Intra-individual Comparison To Energy-integrating Detector CT
Pakaparn Kittichokechai, MD
Anatomic Characteristics Of Patients With Right Aortic Arch And Aberrant Left Subclavian Artery Who Do And Do Not Undergo Vascular Ring Repair
Brittany Weber, MD, PhD
The Frequency, Prevalence, And Outcomes Of Incidentally Detected Coronary Artery Calcium Using Artificial Intelligence Analysis Among Patients With Immune Mediated Inflammatory Diseases
Young Investigator Award
Marcel Langenbach, MD
Pericoronary Adipose Tissue Density Relates To Increased Cardiovascular Adverse Events In Patients With Stable Chest Pain: Insights From The PROMISE Trial
Sang-Hyeon Park, MD
Clinical Impact Of Assessing Plaque Quantification And Local Hemodynamics Of Intermediate Lesions In The Prediction Of Acute Coronary Syndrome
Seokhun Yang, MD
Coronary CT Angiography-derived Precursors Of Acute Coronary Syndrome In Ischemia-causing Lesions
Steven Mould, MD
Aortic Valve Area To Annulus Area Ratio: A Novel Metric To Improve The Accuracy Of Cardiac CT For Evaluation Of Severe Aortic Stenosis
About DEEPVESSEL FFR
DEEPVESSEL FFR is a software medical device that uses deep learning technology to perform a non-invasive physiological functional assessment of the coronary arteries using coronary computed tomography angiography (CCTA). The software processes coronary CTA images semi-automatically, generates a three-dimensional model of the coronary artery tree, and estimates CT FFR values. DEEPVESSEL FFR is FDA-Cleared, CE-Marked, and NMPA-Cleared.
About Keya Medical
Keya Medical is an international medical technology company developing deep learning-based medical devices for disease diagnosis and treatment. The company is committed to creating solutions that deliver clinical value at all stages in the patient care process, covering specialties including cardiology, neurology, pulmonology, pathology, and surgery. Keya Medical has four centers of excellence in Beijing, Shanghai, Shenzhen, and Seattle. Follow us on LinkedIn, Twitter, and Facebook.
Media Contact
contact@keyamedna.com